• TEXT SIZE

Results with ENBREL in Moderately to Severely Active Juvenile Idiopathic Arthritis (JIA)

In 1999, ENBREL became the first biologic medicine approved to treat moderate to severe juvenile idiopathic arthritis (JIA). It is approved for children 2 years and older.

Proven results

ENBREL is shown to be effective in treating the signs and symptoms of moderately to severely active juvenile idiopathic arthritis. Results with ENBREL include: reduced pain, morning stiffness, and joint swelling.

Results for your child may vary. Because ENBREL works on the immune system, it can lower the ability of the immune system to fight infections and may raise other safety concerns. There have been some cases of unusual cancers reported in children and teenage patients who started using TNF blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA and psoriasis may be more likely to get lymphoma.

Patients receiving ENBREL may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving ENBREL. Please see information on vaccinations in FAQs.

It is recommended that juvenile idiopathic arthritis patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating ENBREL therapy. Patients with a significant exposure to varicella virus should temporarily discontinue ENBREL therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. Be sure to read the Important Safety Information and Medication Guide and talk with your child's rheumatologist.

Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Prescription ENBREL is taken by injection.

IMPORTANT SAFETY INFORMATION
Indication

Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

Supportive data
Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
  • In a clinical study, ENBREL was shown to be effective in about 3 out of 4 children with JIA who used it at 3 months. ENBREL has been shown to begin working in as few as 2 to 4 weeks.
Has your child been diagnosed
with JIA?

Sign up today for more information about moderately to severely active JIA and ENBREL.

SIGN UP TODAY